Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) declared a dividend on Wednesday, February 26th, DividendData.Co.Uk reports. Stockholders of record on Thursday, March 20th will be given a dividend of $0.48 per share on Thursday, May 1st. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, March 20th. This is a 50.0% increase from Hikma Pharmaceuticals’s previous dividend of $0.32. The official announcement can be accessed at this link.
Hikma Pharmaceuticals Stock Up 1.1 %
Shares of LON HIK traded up GBX 22 ($0.29) during midday trading on Tuesday, reaching GBX 2,052 ($26.65). 76,300,625 shares of the company’s stock traded hands, compared to its average volume of 3,417,024. The company has a market cap of £5.69 billion, a price-to-earnings ratio of 20.14, a P/E/G ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a one year low of GBX 1,750 ($22.73) and a one year high of GBX 2,360 ($30.65). The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The stock’s 50 day simple moving average is GBX 2,177.22 and its 200-day simple moving average is GBX 2,014.40.
Analysts Set New Price Targets
HIK has been the subject of several recent analyst reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th. Berenberg Bank restated a “buy” rating and issued a GBX 2,560 ($33.25) target price on shares of Hikma Pharmaceuticals in a research note on Monday, March 10th.
About Hikma Pharmaceuticals
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
See Also
- Five stocks we like better than Hikma Pharmaceuticals
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 REITs to Buy and Hold for the Long Term
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.